title: Obeticholic Acid: First Global Approval.
abstract: Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. The drug is in preregistration for this indication in the EU. This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
authors.forename: A
authors.initials: A
authors.lastname: Markham
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Keam
mesh_terms: D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017277:Drug Approval / Q000379:methods; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy*; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
chemical_list: C464660:obeticholic acid; D002635:Chenodeoxycholic Acid; D014580:Ursodeoxycholic Acid